

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,

Petitioner,

v.

NOVO NORDISK A/S,

Patent Owner.

---

Case No. IPR2023-00724

Patent No. 10,335,462

---

**PETITIONER'S NOTICE OF DEPOSITION OF  
ANNE FLINT**

Pursuant to 37 C.F.R. § 42.53, Petitioner Mylan Pharmaceuticals Inc. hereby provides notice that it will cross-examine Anne Flint, a witness of Patent Owners. The cross-examination will begin at 9 am local time on March 14, 2024 in London, U.K. at a location to be determined. The parties have agreed on this date for the cross-examination of Ms. Flint.

The cross-examination will be recorded by stenographic means by a court reporter licensed to administer oaths, and will also be recorded using audio and/or visual means. It may also be transcribed by Live Note or other real-time reporting.

Dated: March 6, 2024

Respectfully submitted,

PERKINS COIE LLP  
700 Thirteenth Street, N.W., Suite 800  
Washington, D.C. 20005-3960  
202.654.6200 (phone)  
202.654.6211 (fax)

/Brandon M. White/  
Lead Counsel  
Brandon M. White, Reg No. 52,354

Attorneys for Petitioner

**CERTIFICATE OF SERVICE**

Pursuant to 37 C.F.R. § 42.6(e), I certify that I caused to be served a true and correct copy of the foregoing: PETITIONER'S NOTICE OF DEPOSITION OF ANNE FLINT by email to the electronic service addresses for Patent Owner

J. Steven Baughman  
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP  
steve.baughman@groombridgewu.com

Megan Raymond  
GROOMBRIDGE, WU, BAUGHMAN & STONE LLP  
megan.raymond@groombridgewu.com

Novo-Semaglutide-IPR@groombridgewu.com

Dated: March 6, 2024

PERKINS COIE LLP  
700 Thirteenth Street, N.W., Suite 800  
Washington, D.C. 20005-3960  
202.654.6200 (phone)  
202.654.6211 (fax)

/Brandon M. White/

Lead Counsel

Brandon M. White, Reg No. 52,354

Attorneys for Petitioner